Literature DB >> 33763203

Case Report: Ziprasidone induced neuroleptic malignant syndrome.

Yub Raj Sedhai1, Alok Atreya2, Prabin Phuyal3, Soney Basnyat4, Sagar Pokhrel5.   

Abstract

Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency. It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone. A case of NMS with Ziprasidone use at the therapeutic dose is reported here. Copyright:
© 2021 Sedhai YR et al.

Entities:  

Keywords:  Neuroleptic Malignant Syndrome (NMS); Neurologic emergency; Parkinson’s disease; Ziprasidone

Year:  2021        PMID: 33763203      PMCID: PMC7953912          DOI: 10.12688/f1000research.51094.1

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  16 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome.

Authors:  Jeffrey R Strawn; Paul E Keck
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 3.  Neuroleptic malignant syndrome.

Authors:  Jeffrey R Strawn; Paul E Keck; Stanley N Caroff
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

Review 4.  Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Nishan S Gunasekara; Caroline M Spencer; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome.

Authors:  B Spivak; D I Maline; Y Vered; V N Kozyrev; R Mester; S A Neduva; R S Ravilov; E Graff; A Weizman
Journal:  Acta Psychiatr Scand       Date:  2000-09       Impact factor: 6.392

Review 6.  Ziprasidone: the fifth atypical antipsychotic.

Authors:  Charles F Caley; Chandra K Cooper
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

7.  Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.

Authors:  Nicola S Gray
Journal:  Hum Psychopharmacol       Date:  2004-04       Impact factor: 1.672

Review 8.  Neuroleptic malignant syndrome.

Authors:  S N Caroff; S C Mann
Journal:  Med Clin North Am       Date:  1993-01       Impact factor: 5.456

9.  Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.

Authors:  Murat Eren Ozen; Mehmet Yumru; Haluk A Savas; Neslihan Cansel; Hasan Herken
Journal:  World J Biol Psychiatry       Date:  2007       Impact factor: 4.132

10.  Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.

Authors:  Timothy D Girard; Matthew C Exline; Shannon S Carson; Catherine L Hough; Peter Rock; Michelle N Gong; Ivor S Douglas; Atul Malhotra; Robert L Owens; Daniel J Feinstein; Babar Khan; Margaret A Pisani; Robert C Hyzy; Gregory A Schmidt; William D Schweickert; R Duncan Hite; David L Bowton; Andrew L Masica; Jennifer L Thompson; Rameela Chandrasekhar; Brenda T Pun; Cayce Strength; Leanne M Boehm; James C Jackson; Pratik P Pandharipande; Nathan E Brummel; Christopher G Hughes; Mayur B Patel; Joanna L Stollings; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  N Engl J Med       Date:  2018-10-22       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.